AccountSonarAll accounts

Company profile

Amgen

Biotechnology · Thousand Oaks, California · amgen.com

Amgen Inc. is a leading biotechnology company specializing in human therapeutics, with a focus on innovative medicines for serious illnesses. The company continues to advance its research and development efforts to address unmet medical needs.

Strategic priorities

Advancing Oncology Research

To accelerate treatment development for patients with complex cancers.

Launched Amgen Partners of Choice network with eight leading oncology academic centers.

AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS

Enhancing Drug Discovery with AI

To leverage machine learning and AI in drug discovery.

Collaborated with Generate Biomedicines to develop novel protein therapeutics using AI.

Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement

Developing Induced Proximity Medicines

To create therapies targeting disease-driving proteins.

Invested in DNA-encoded libraries and external partnerships for induced proximity medicines.

Induced Proximity: Turning Molecular Matchmakers into Medicines

Expanding Global Presence

To reach more patients worldwide.

Established a presence in approximately 100 countries, delivering medicines to millions.

About | Amgen

AI program

Amgen is integrating AI and machine learning into its drug discovery processes, exemplified by its collaboration with Generate Biomedicines to develop novel protein therapeutics. The company is also investing in induced proximity medicines, utilizing DNA-encoded libraries and external partnerships to target disease-driving proteins.

Technology posture

Amgen is leveraging advanced technologies, including AI and machine learning, to enhance its drug discovery and development processes.

Cloud
3/5
AI
4/5
Data
4/5

Amgen's AI initiatives are central to its research and development strategy.

Technology vendor categories

AI
Generate Biomedicines
Cloud
n/a
Data
n/a
ERP
n/a
CRM
n/a
Security
n/a
Network
n/a
DevOps
n/a

Recent developments

Sources

Get the full sourced brief on Amgen

This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.

Generate a full brief

Your first brief is free, no card required.

Evidence confidence 90/100. Generated 2026-07-08 from public sources.